Navigation Links
Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
Date:12/2/2011

SEATTLE, Dec. 2, 2011 /PRNewswire/ -- Immune Design Corp. announced today that Wayne R. Gombotz, Ph.D. has joined the company as its new Chief Development Officer.  Dr. Gombotz brings a significant amount of product development experience to this key leadership position at Immune Design.  He will oversee product development and manufacturing for Immune Design's therapeutic vaccine product candidates.

(Logo: http://photos.prnewswire.com/prnh/20111018/SF88252LOGO)

Wayne R. Gombotz, Ph.D., most recently served as Vice President of Pharmaceutical Operations at Omeros Corporation from 2005 to 2011. He was responsible for product development and manufacturing for Omeros' pharmaceutical and biopharmaceutical technology platforms.  Prior to this, from 2002 to 2005, Dr. Gombotz was Vice President of Process Science and Pharmaceutical Development at Corixa Corporation.  During the three years he spent at Corixa, he built and led a team that championed immunotherapeutic products.  Corixa was acquired by GlaxoSmithKline plc in 2005.  Prior to joining Corixa, Dr. Gombotz served as a Senior Director of Analytical Chemistry and Formulation at Amgen (formerly Immunex) from 1995 to 2002 where he played a major role in the development and launch of ENBREL®.  He has 25 years of experience providing technical and administrative direction of clinical and commercial manufacturing operations, process development, and process validation functions.  Dr. Gombotz received Ph.D. and M.S. in bioengineering from the University of Washington, Seattle, WA, and received his B.A. in biology from Colby College, Waterville, ME.

"Wayne brings an exceptional and seasoned skill set to Immune Design with very unique capabilities," stated Carlos V. Paya, M.D., Ph.D., President and Chief Executive Officer. "As we loo
'/>"/>

SOURCE Immune Design Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
2. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
3. EUPROBIO 2008 Presentation to Highlight Latest Immune Research
4. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
5. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
6. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
7. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
8. Peptimmune Presentations at Upcoming Events
9. Protein-printing technique gives snapshots of immune system defense
10. Visualizing asthma-causing immune cells at work
11. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... patient has sepsis, a life-threatening condition in which bacteria ... too fast for antibiotics to help. A new device ... team at Harvard,s Wyss Institute for Biologically Inspired Engineering ... , "Even with the best current treatments, sepsis patients ... percent of the time," said Mike Super, Ph.D., Senior ...
(Date:9/15/2014)... 2014 Zymo Research Corp., has announced the ... safe ambient temperature storage and transport of infectious ... of agents in such samples is completely inactivated ... the viral nucleic acids for subsequent analyses.  With ... in West Africa and ...
(Date:9/15/2014)... 2014 Applied Silicone Corporation, a ... the medical device and critical healthcare market, introduces ... implantable medical device market. The Dual Matrix ... a silicone gel with improved fracture resistance, cohesive ... consists of two crosslinked networks working in conjunction ...
(Date:9/15/2014)... 2014  The second annual International Plasma Awareness ... joint initiative of the Plasma Protein Therapeutics Association ... is designed to: , Raise global awareness ... of plasma donors in saving and improving lives ... rare diseases Member companies are planning ...
Breaking Biology Technology:Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 3
... SEATTLE, Sept. 26 Today at the ... introduction of a,ground-breaking vaccine to eliminate epidemic ... conjugate vaccine, developed by the Meningitis,Vaccine Project, ... and,PATH and produced by Serum Institute of ...
... in Cancer is Published in the ... of the National Academy of Sciences, MOUNTAIN VIEW, ... focused on discovering, developing,and commercializing therapeutics that target the ... series of rigorous experiments to,elucidate CXCR7,s essential role in ...
... Oxford Finance Corporation,one of the nation,s leading providers ... announced it has finalized a $7 million secured ... will be used,to support Othera,s goal to become ... formulations for,ophthalmology, oncology and inflammatory disease. "This ...
Cached Biology Technology:PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso 2PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso 3ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth 2ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth 3ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth 4ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth 5Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals 2
(Date:9/15/2014)... Mass. (September 15, 2014) The so-called central ... makes proteinhas long provided a simplified explanation for ... living organisms. , In reality, of course, ... schema first articulated nearly 60 years ago by ... double-helix structure. For one, there are multiple types ...
(Date:9/15/2014)... has evolved a simple, mechanical solution to avoid ... 11 Science Express. , ... misalignments that lead to infertility, miscarriage, or congenital ... cause these problems, but what exactly goes wrong ... the Wellcome Trust Center for Cell Biology at ...
(Date:9/15/2014)... that a single group of microorganisms may be responsible ... the oceans, with implications for the global carbon cycle ... essential molecule required by most life on this planet, ... of microorganisms because it is so large and complex. ... maintaining the brain and nervous systems, as well as ...
Breaking Biology News(10 mins):Scientists discover RNA modifications in some unexpected places 2Cells simply avoid chromosome confusion 2Cells simply avoid chromosome confusion 3Researchers discover new producer of crucial vitamin 2
... also available in Spanish . , ... of Experimental Sciences of the University of ... this reason, immigrant teenagers have a lower probability of suffering ... eating habits. The study has not only analysed for the ...
... of UAB geneticists, doctors and biostatisticians has received $5.7 ... and test new treatments for neurofibromatosis, or NF. ... group called the NF Consortium. The coalition formed more ... clinical trials held across the nation looking at new ...
... the plot to blow up trans-Atlantic airlines with liquid explosives ... pressure on the airline industry, and Homeland Security, to find ... on airline passengers, but also to figure out what they ... Directorate (S&T) is teaming with scientists at the Los Alamos ...
Cached Biology News:Study reveals that immigrant teenagers eat better than Spanish teenagers 2UAB wins $5.7M neurofibromatosis grant 2UAB wins $5.7M neurofibromatosis grant 3Menace in a bottle 2
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
... X-Gal (5-bromo-4-chloro-3-indoyl-beta-D-galactopyranoside) is ... to identify recombinant plasmids. ... X-Gal and IPTG, ... appear blue, whereas recombinant ...
... Jouan B4i ventilated and BR4i refrigerated multifunction centrifuges ... speed operation at a low sound level with ... for biocontainment. Their AUTO-LOCK rotor exchange system without ... for use within seconds. Instant rotor ...
... III RNase H- Reverse ... improved version of SuperScript™ ... Like SuperScript™ II it ... strand from single-stranded RNA ...
Biology Products: